Home > Insider Trading > Filing (0001179110-18-007360)

Filing Details

Accession Number:: 0001179110-18-007360
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-05-22 17:25:47
Reporting Period:: 2018-05-18

Accepted Time:: 2018-05-22 17:25:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1651561	Tabula Rasa Healthcare Inc.	TRHC	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1352929	Bruce Luehrs	4801 S. Broad St. Suite 400 Philadelphia PA 19112		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Commmon Stock	Disposition	2018-05-18	10,647	$50.75	75,195	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-18	22,441	$51.23	52,754	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-21	16,800	$50.42	35,954	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-21	12,133	$51.41	23,821	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-21	1,500	$52.34	22,321	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-22	18,395	$49.58	3,926	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2018-05-22	3,926	$50.18	0	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,161	Direct

Footnotes

Includes a restricted stock award of 3,710 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, of which shares 1,236 are vested and 2,474 are unvested. Also includes a restricted stock award of 1,855 shares of the Company's common stock received by Bruce Luehrs on September 28, 2016, all of which are vested. Also includes a restricted stock award of 2,596 shares of the Company's common stock received by Bruce Luehrs on June 16, 2017. Such common stock vests in full on the earlier of the next annual shareholder meeting or the one year anniversary of the date of grant.
These securities are held by Emerald Stage2 Ventures, L.P. Stage2 Capital Ventures Associates, L.P. is the general partner of Emerald Stage2 Ventures, L.P. and Stage2 Capital Associates G.P., LLC is the general partner of Stage2 Capital Ventures Associates, L.P. Bruce Luehrs, who serves as a director of the Issuer, is an officer of Stage2 Capital Associates G.P., LLC.
The Reporting Person disclaims beneficial ownership (as defined in Rule 16a-1(a)(2)) of the securities reported herein (except to the extent of his pecuniary interest in such securities), and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $50.40 to $50.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $51.00 to $51.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (5) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $50.18 to $50.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $51.00 to $51.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (7) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $52.21 to $52.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (8) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $49.11 to $49.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (9) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $50.00 to $50.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (10) to this Form 4.